Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cervical Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Immunochemotherapy Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Women's Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310000, China

Location status: Recruiting

Location contact

Tingting Chen

CONTACT

[email protected]

86-13738102530

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
Positive PD-L1 expression;
ECOG score ≤1

Exclusion criteria

Positive parametrium or surgical margin;
Incomplete radical surgery;
Residual target lesions;
Active autoimmune disease or autoimmune disease requiring systemic treatment;
Previous treatment with immune checkpoint inhibitors.

Treatment and study plan

Camrelizumab combined with chemotherapy

Drug

Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery

Primary outcomes

3-year disease-free survival rate

Time frame: from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months

Sponsors and collaborators

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University

Other

Registry information

Official study title

Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2029
First posted: Sep 11, 2025
Registry last updated: Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting